Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
The American Journal of Tropical Medicine and Hygiene|July 27, 2022
40 Years of Pfs48/45 Research as a Transmission-Blocking Vaccine Target of Plasmodium falciparum MalariaRobert W Sauerwein, Jordan Plieskatt, Michael Theisen
Analytical Biochemistry|November 23, 2017
Disulfide bond mapping of Pfs25, a recombinant malaria transmission blocking vaccine candidateShwu-Maan Lee, Jordan Plieskatt, C Richter King
Methods in Molecular Biology (Clifton, N.J.)|April 24, 2023
Cloning and Recombinant Protein Expression in Lactococcus lactisSusheel K Singh, Mohammad Naghizadeh, Jordan Plieskatt, et al.
Methods in Molecular Biology (Clifton, N.J.)|February 5, 2024
Production and Purification of Plasmodium Circumsporozoite Protein in Lactococcus lactisMohammad Naghizadeh, Susheel K Singh, Jordan Plieskatt, et al.
Trends in Parasitology|August 2, 2018
Lessons along the Critical Path: Developing Vaccines against Human HelminthsDavid J Diemert, Maria Elena Bottazzi, Jordan Plieskatt, et al.
Protein Expression and Purification|April 13, 2019
Expression and purification optimization of an N-terminal Pfs230 transmission-blocking vaccine candidateShwu-Maan Lee, Jordan Plieskatt, Seetha Krishnan, et al.
Bioinformatics (Oxford, England)|May 6, 2014
Bioclojure: a functional library for the manipulation of biological sequencesJordan Plieskatt, Gabriel Rinaldi, Paul J Brindley, et al.
Annals of the New York Academy of Sciences|June 30, 2007
Thymosin fraction-5 possesses antiproliferative properties in HL-60 human promyelocytic leukemia cells: characterization of an active peptideBryan L Spangelo, Joseph D Roach, Freidun Hadi, et al.
Vaccine|February 22, 2024
Clinical formulation development of Plasmodium falciparum malaria vaccine candidates based on Pfs48/45, Pfs230, and PfCSPJordan Plieskatt, Peter Bang, Grith Krøyer Wood, et al.
Human Vaccines & Immunotherapeutics|April 10, 2025
Magnitude and durability of ProC6C-AlOH/Matrix-M<sup>tm</sup> vaccine-induced malaria transmission-blocking antibodies in Burkinabe adults from a Phase 1 randomized trialMohammad Naghizadeh, Kazutoyo Miura, Ebenezer Addo Ofori, et al.
Pageof 4